Integrating antithrombin and antiplatelet therapies with early invasive management for non–ST-segment elevation acute coronary syndromes - 25/08/11
, Matthew T Roe, MD, MHS a, John H Alexander, MD, MHS a, Kenneth W Mahaffey, MD a, Christopher B Granger, MD a, Eric D Peterson, MD a, Robert M Califf, MD a, Robert A Harrington, MD aAbstract |
Non–ST-segment elevation acute coronary syndromes are a dramatic manifestation of coronary artery disease. Multiple clinical trials have shown that early cardiac catheterization improves clinical outcomes in patients with non–ST-segment elevation acute coronary syndromes. Many antithrombotic agents effectively manage unstable coronary syndromes and serve as adjuncts to percutaneous coronary intervention. Yet, the growing number of pharmacologic agents makes early management of non–ST-segment elevation acute coronary syndromes increasingly complex. We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 116 - N° 2
P. 119-129 - janvier 2004 Regresar al número
Artículo precedente
- Silent myocardial ischemia: concepts and controversies
- Francis Q Almeda, Thomas T Kason, Sandeep Nathan, Clifford J Kavinsky
- Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus)
- Ross T Tsuyuki, Kari L Olson, Alexander M Dubyk, Terri J Schindel, Jeffrey A Johnson
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?